IMRN
- Immuron Limited
()
Overview
Company Summary
Immuron Limited (IMRN) is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment and prevention of various infectious diseases. The company specializes in utilizing a unique platform technology called "polyclonal antibodies" to develop and produce therapies that target specific pathogens.
Immuron's flagship product is called Travelan, which is a commercially available over-the-counter supplement. It is designed to prevent and reduce the symptoms of travelers' diarrhea, a common ailment for individuals traveling to high-risk destinations. Travelan works by neutralizing the toxins produced by certain types of bacteria that can cause diarrhea.
In addition to Travelan, Immuron is also involved in research and development activities for other therapeutic products. These include potential treatments for various gastrointestinal disorders, such as non-alcoholic steatohepatitis (NASH), which is a progressive liver disease, and inflammatory bowel disease (IBD).
The company's technology allows for the production of targeted, high-quality antibodies that have a broader range of action compared to traditional monoclonal antibodies. By utilizing polyclonal antibodies, Immuron aims to provide effective and safe therapies for a range of infectious diseases and associated conditions.
Immuron collaborates with academic institutions, research organizations, and commercial partners to advance its product pipeline. The company's primary focus is on gaining regulatory approvals and expanding market access for its existing products while simultaneously working on the development of new therapies.
Overall, Immuron Limited is dedicated to creating innovative solutions to combat infectious diseases and improve the well-being of individuals globally.